Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution

PurposeData about incidence, biological, and clinical characteristics of oligometastatic breast cancer (OMBC) are scarce. However, these data are essential in determining optimal treatment strategy. Gaining knowledge of these elements means observing and describing large, recent, and consecutive series of OMBC in their natural history.MethodsWe collected data retrospectively at our institution from 998 consecutive patients diagnosed and treated with synchronous or metachronous metastatic breast cancer (MBC) between January 2014 and December 2018. The only criterion used to define OMBC was the presence of one to five metastases at diagnosis.ResultsOf 998 MBC, 15.8% were classified OMBC. Among these, 88% had one to three metastases, and 86.7% had only one organ involved. Bone metastases were present in 52.5% of cases, 20.9% had progression to lymph nodes, 14.6% to the liver, 13.3% to the brain, 8.2% to the lungs, and 3.8% had other metastases. 55.7% had HR+/HER2- OMBC, 25.3% had HER2+OMBC, and 19% had HR-/HER2- OMBC. The HR+/HER2- subtype statistically correlated with bone metastases (p = 0.001), the HER2+subtype with brain lesions (p = 0.001), and the HR-/HER2- subtype with lymph node metastases (p = 0.008). Visceral metastases were not statistically associated with any OMBC subtypes (p = 0.186). OMBC-SBR grade III was proportionally higher than in the ESME series of 22,109 MBC (49.4% vs. 35.1%, p < 0.001).ConclusionOMBC is a heterogeneous entity whose incidence is higher than has commonly been published. Not an indolent disease, each subgroup, with its biological and anatomical characteristics, merits specific management.

Automated summary

This study retrospectively collected data from 998 consecutive patients with synchronous or metachronous metastatic breast cancer (MBC) and found that 15.8% of cases met the definition of oligometastatic breast cancer (OMBC). Among OMBC patients, 88% had 1-3 metastases and 86.7% had only one organ involved. Different subtypes of OMBC were associated with different metastatic sites. HR+/HER2- subtype was associated with bone metastases, HER2+ subtype was associated with brain lesions, and HR-/HER2- subtype was associated with lymph node metastases. In conclusion, OMBC is a heterogeneous entity that requires specific management strategies for different subgroups.